# Eiger BioPharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eiger-biopharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Palo Alto, US
- Website: www.eigerbio.com
- Total disclosed funding: $19M
- Latest round: Series A (Feb 13, 2015)
- Investors on record: 2

## About

Eiger BioPharmaceuticals, based in the US and founded in 2008, specializes in developing innovative antiviral therapies aimed at treating infectious diseases, enhancing patient outcomes through targeted solutions.Founded in 2008 and headquartered in Palo Alto, California, Eiger BioPharmaceuticals is a biotechnology company focused on innovative therapeutic solutions for infectious diseases. The company has undergone strategic changes, including various funding rounds to support its growth. Notably, it raised USD 75.00 mn in its most recent VENTURE DEBT round in November 2018, with Innovatus Capital Partners as the lead investor. Eiger has successfully completed 20 deals overall, reflecting its active engagement in the market. The leadership team includes CEOs David Apelian and David Cory, who bring significant expertise to the company.Eiger BioPharmaceuticals is dedicated to developing antiviral therapies that specifically target viral pathogens, aiming to provide effective treatment options for a range of viral infections. These therapies inhibit viral replication to reduce infection severity and improve patient outcomes. Their primary markets consist of healthcare providers, research institutions, and pharmaceutical companies across North America, Europe, and Asia, focusing on delivering advanced therapies to meet critical medical needs.In 2023, Eiger BioPharmaceuticals reported revenue of USD 15.52 mn, with an EBITDA of USD -71.51 mn. The company's revenue generation is primarily driven by partnerships and collaborations with larger pharmaceutical firms, leveraging its proprietary technology and product offerings through licensing agreements and milestone payments.Eiger BioPharmaceuticals is actively working on launching new antiviral products and expanding into additional geographic markets. The funding raised in recent rounds, particularly the USD 75.00 mn obtained in November 2018, is intended to support these initiatives. The company aims to enhance its product pipeline and improve market penetration in North America and Europe by 2024. Eiger's strategy also involves leveraging its collaborations and partnerships to facilitate these growth efforts, ensuring the company remains at the forefront of therapeutic innovation.

## Funding rounds

- Series A, Feb 13, 2015, $8.7M — InterWest Partners, Vivo Capital
- Series B, Apr 15, 2011, $3.5M — InterWest Partners, Vivo Capital
- Series A, Feb 24, 2009, $7.1M — InterWest Partners, Vivo Capital

## Investors

- InterWest Partners (https://capitalatlas.ai/funds/interwest-partners) — Series A, Series B
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series A, Series B